Ozempic (GLP-1) Lawsuit — Free Case Review
Which Medications — and Which Injuries — Qualify
Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Did this happen to you — or someone you love?
Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.
Partners
Matthew T. Marin & Stefanie A. Murphy
Super Lawyers® honorees · American Association for Justice members
Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.
This page reports, injury by injury, how many adverse-event reports the FDA’s public FAERS database contains for the three GLP-1 medications at the center of the Ozempic litigation — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and dulaglutide (Trulicity) — current through the FDA’s July 30, 2026 data release. These are raw report counts, not proven injuries: our methodology page explains exactly how we count, and why FAERS numbers must be read with care.
Reports by injury and medication
Counts are unique FAERS reports whose listed reactions include the exact MedDRA preferred term shown. A report can list several reactions and several suspect drugs, so rows and columns overlap and do not sum.
| Reported reaction (MedDRA term) | Semaglutide | Tirzepatide | Dulaglutide |
|---|---|---|---|
| Impaired gastric emptying (the MedDRA term FAERS uses for gastroparesis / delayed gastric emptying) | 3,558 | 1,678 | 1,829 |
| Gastrointestinal hypomotility | 489 | 367 | 546 |
| Ileus | 632 | 291 | 255 |
| Intestinal obstruction (incl. small & large)* | 1,339 | 785 | 463 |
| Optic ischaemic neuropathy (the MedDRA term for NAION) | 631 | 150 | 30 |
| Blindness (incl. unilateral)* | 511 | 261 | 278 |
| Pancreatitis (incl. acute)* | 1,585 | 1,658 | 1,841 |
| Cholelithiasis (gallstones) | 563 | 716 | 264 |
| Vomiting | 6,964 | 8,267 | 5,787 |
*Rows marked with an asterisk sum closely related MedDRA terms (e.g., “Intestinal obstruction” + “Small intestinal obstruction” + “Large intestinal obstruction”). The API reports a drug’s 1,000 most-frequent reaction terms; a sub-term with fewer than roughly 15–22 reports for a given drug falls below that cutoff and is counted here as zero, so starred sums can slightly understate.
Overall reporting volume
| Semaglutide | Tirzepatide | Dulaglutide | |
|---|---|---|---|
| Total FAERS reports | 73,001 | 160,663 | 88,160 |
| Reports coded serious | 36,179 | 28,502 | 22,898 |
| Reports with a death outcome | 1,270 | 889 | 1,676 |
How to read these numbers — honestly
FAERS is a reporting system, not a registry of proven injuries. A report means someone — a doctor, a patient, a manufacturer — told the FDA about an event that occurred during or after use of a medication. It does not mean the medication caused the event, and the FDA says exactly that. There is no denominator (millions of people take these drugs), reporting rises when a drug is in the news or in litigation, duplicates occur, and a single report can name several drugs and several reactions. What the numbers are legitimately good for: seeing which injuries are being reported, in what relative volume, across the three medications — the same signal-detection use regulators put them to. Every count on this page can be reproduced from the public API in about a minute; the methodology page shows the exact queries.
Free, confidential case review. Marin & Murphy is currently accepting Ozempic (GLP-1) stomach-injury and NAION vision-loss cases. No fee unless there is a recovery. Marin & Murphy is licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; matters elsewhere may be referred to lawyers licensed in your state.
Start your free case review or call (888) 348-2735 — answered 24/7.
See if you qualify
A few quick questions about which GLP-1 medication you took, your diagnosis and testing, and your treatment. This is the initial intake screening, not a full case review. Most people finish in about two minutes.
- 🔒 Confidential
- No obligation
- ⏱ ~2 minutes
Marin & Murphy Law Firm · Free & confidential · Stop messages anytime
Common questions
Does a FAERS report prove the drug caused the injury?
No. FAERS reports are unverified accounts of events that occurred during or after use. Causation is exactly what the courts are fighting over — through expert evidence, not report counts.
Why does the litigation talk about gastroparesis if the courts require a gastric emptying study?
Because a FAERS report and a qualifying legal claim are different things. The MDL requires objective test confirmation for gastroparesis claims — a stricter standard than a FAERS entry.
Why is the NAION number so much smaller than the stomach-injury numbers?
NAION is a rare condition to begin with, its possible link to these drugs was first published in 2024, and reporting lags awareness. The relative pattern across the three drugs — not the absolute size — is what regulators and researchers watch.
How often is this page updated?
The FDA refreshes the underlying data roughly quarterly; we re-run the queries and update this page after each release. Current data release: July 30, 2026.
Sources
- FDA Adverse Event Reporting System (FAERS), via the openFDA drug/event API, data release July 30, 2026; queries listed on our methodology page
- FDA, “Questions and Answers on FDA’s Adverse Event Reporting System (FAERS)”
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone’s injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber.
Attorney Advertising.
This page is attorney advertising and is for informational purposes only; it is not legal or medical advice. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship.
The data: FDA adverse-event data, the FAERS methodology, the US vs. EU warning-label gap, and the lawsuit tracker.